Antiviral B Cell Memory in the Absence of Mature Follicular Dendritic Cell Networks and Classical Germinal Centers in TNFR1^−/− Mice

Mice and animal experiments

TNFR1^−/− mice as well as (C57BL/6 × 129/Sv)F₁ and C57BL/6 mice used as normal controls were bred and kept under specific pathogen-free conditions. The generation of TNFR1^−/− and IFN-αβR^−/− mice has been described in detail elsewhere (37, 38). In all experiments presented in this study, no significant differences between the C57BL/6, 129/Sv, and (C57BL/6 × 129/SV)F₁ mouse strains used as normal controls have been detected. Therefore, data from one control strain (usually C57BL/6) are presented. TNFR1^−/− mice and (C57BL/6 × 129/Sv)F₁ mice were obtained from BRL (Füllinsdorf, Switzerland). C57BL/6 mice were purchased from the breeding colony of the Institut für Labortierkunde (University of Zürich, Zürich, Switzerland). All animal experiments were performed with age- and sex-matched mice of 7–14 wk of age with permission of the veterinary office, according to cantonal and federal law requiring the use of minimal numbers of experimental animals.

Viruses

VSV, VSV IND (Mudd-Summers isolate), and VSV NJ (Pringle isolate), originally obtained from Dr. D. Kolakofsky (University of Geneva), were grown on BHK-21 cells infected at low multiplicity and plaqued on Vero cells (39). Recombinant vaccinia virus expressing the glycoprotein of VSV IND (VaccIND_G) was a generous gift of Dr. B. Moss, Laboratory of Viral Diseases, National Institutes of Health (Bethesda, MD) (40). Vaccinia virus was grown at a low multiplicity of infection on BSC 40 cells and plaqued on BSC 40 cells. The recombinant baculovirus expressing the glycoprotein of VSV IND (VSV-G) was a generous gift of Dr. D. H. L. Bishop, NERC Institute of Virology (Oxford, U.K.). The recombinant baculovirus was derived from nuclear polyhedrosis virus and was grown at 28°C in Spodoptera frugiperda cells in spinner cultures using TC-100 medium. Recombinant protein was produced as described (41).

Immunohistology

Freshly removed organs were immersed in HBSS and snap frozen in liquid nitrogen. Tissue sections of 5 μm thickness were cut in a cryostat, placed on siliconized glass slides, air dried, fixed with acetone for 10 min, and stored at −70°C. Secondary affinity-purified polyclonal anti-Ig antisera were diluted in TBS (pH 7.4) containing 5% normal mouse serum. All other dilutions were made in TBS alone. Incubations were done at room temperature for 30 min; TBS was used for all washing steps. Alkaline phosphatase was visualized using naphthol AS-BI phosphate and New Fuchsin as substrate, which yields a red precipitate. Only for the detection of VSV-Ag-coupled alkaline phosphatase the more sensitive NBT/BCIP reaction was used. Endogenous alkaline phosphatase was blocked by levamisole. All color reactions were performed at room temperature for 15 min with reagents from Sigma (St. Louis, MO). Sections were counterstained with hemalum. Coverslips were mounted with glycerol and gelatin.

Serum neutralization test

Neutralizing titers of sera and hybridoma supernatants were determined as described (45). In brief, serial 2-fold dilutions of 40-fold prediluted (supplemented MEM) and heat-inactivated (30 min at 56°C) sera or undiluted supernatants were mixed with equal volumes of VSV IND diluted to contain 500 PFU/ml. The mixture was incubated for 90 min at 37°C in an atmosphere containing 5% CO₂. A total of 100 μl of the serum-virus mixture was transferred onto Vero cell monolayers in 96-well plates and incubated for 1 h at 37°C. The monolayers were then overlaid with 100 μl DMEM containing 1% methylcellulose. After incubation for 24 h at 37°C, the overlay was removed and the monolayer was fixed and stained with 0.5% crystal violet. The highest dilution of the serum or supernatant that reduced the number of plaques by 50% was taken as the neutralizing titer. To determine IgG titers in the sera, undiluted serum was first pretreated with an equal volume of 0.1 M 2-ME in saline. Such treatment has been shown to completely abrogate IgM-mediated VSV neutralization of IgM mAbs and of polyclonal IgM antisera (day 4 after VSV infection) (34, 36). Titers represent log₂ steps of 40-fold prediluted sera.

Neutralizing activity is expressed as standardized VSV-neutralizing titer of purified mAbs with a starting concentration of 1 μg/ml.

Avidity measurement

Avidity was determined directly from the purified hybridoma supernatants by an ELISA solid-phase method, as described (36, 46, 47). In brief, ELISA plates were coated with purified VSV at three different densities, and Ab concentrations leading to half-maximal absorbance were determined. The three values for Ab input concentration needed for half-maximal binding allowed the determination of free Ab concentration required for half-maximal binding.

Enumeration of AFC

VSV IND-specific AFC were enumerated as described (48). In brief, 25-well plates (Petra Plastik, Chur, Switzerland) were coated overnight with purified UV-inactivated VSV IND. Because largely intact virus particles are exposed, predominantly virus-neutralizing Abs can bind (9). After a blocking step, 5-fold dilutions of single spleen cell suspensions were added and incubated for 5 h at 37°C. Plates were washed and incubated with goat anti-mouse IgG Abs, then washed and incubated with alkaline phosphatase-labeled donkey anti-goat IgG Abs. Ab spots were developed with alkaline buffer solution (Sigma) containing 1 mg/ml BCIP mixed with 3% agarose in distilled water (4:1).

Adoptive transfer for B cell memory detection

A total of 10⁷ spleen cells of VSV IND- or VSV-G-primed TNFR1^−/− and control mice (C57BL/6 and (C57BL/6 × SV129)F₁) was adoptively transferred into sublethally irradiated (4.5 Gy, day −1) C57BL/6 recipients. To allow for excess T help, 10⁷ spleen cells from C57BL/6 mice immunized with 2 × 10⁶ VSV NJ 6 days previously were cotransferred. VSV NJ has been shown to cross-prime T help for anti-VSV IND-neutralizing IgG, whereas the neutralizing anti-VSV Abs are not cross-reactive between the two VSV serotypes (45). This has also been demonstrated to be the case in TNFR1^−/− mice (not shown). Twelve to twenty-four hours after adoptive transfer, the recipients were immunized with 2 × 10⁶ PFU VSV IND, and the neutralizing IgG titers were determined at the indicated time points.

Detection of infectious VSV by adoptive transfer of organ homogenates into VSV-susceptible IFN-αβR^−/− mice

TNFR1^−/− mice and control wt 129 mice were infected i.v. with 2 × 10⁶ PFU VSV, and 1 or 20 days later, brain, spinal cord, spleen, liver, and kidney were removed. Organs were homogenized and brain + spinal cord, spleen, and liver + kidney were pooled from two mice before i.p. inoculation into one IFN-αβR^−/− mouse. Survival of the animals was monitored twice daily.

Generation of VSV IND-specific hybridomas

For the generation of VSV IND-specific monoclonal B cell hybridomas, TNFR1^−/− mice and (C57BL/6 × 129Sv)F₁ control mice were immunized with 2 × 10⁶ PFU VSV IND and boosted 9 or 16 days later with the same Ag and dose. Three days after the boosting, 10⁷ spleen cells were fused with 10⁷ cells of the Ig-nonproducing myeloma line X63Ag8.653. The supernatants of the growing hybridomas were screened for specific VSV binding with ELISA on VSV-coated plastic plates. VSV-binding supernatants were tested for VSV neutralization, and the positive clones were selected and subcloned by limiting dilution. Supernatants from the subclones were purified over a protein G column and then used for isotype determination, avidity measurements, and the determination of the neutralizing activity against VSV IND.

No development of classical GCs in the spleen and the mesenteric lymph node (MLN) in TNFR1^−/− mice after immunization with live VSV IND or with VSV-infected cells

TNFR1^−/− mice and control mice were infected with 2 × 10⁶ PFU live VSV IND i.v. or s.c. to immunohistochemically monitor the development of VSV-specific GCs in the spleen or in the draining LN. Alternatively, to allow the direct visualization of VSV-Ag, which is methodologically not possible after infection with 2 × 10⁶ PFU live VSV IND (9, 10), mice were immunized i.p. with UV-inactivated cell lysates of VSV-infected BHK cells. It has been shown previously that both immunization protocols lead to an intensive GC reaction in the spleen of normal mice beginning at about day 6 after immunization, peaking at day 12, and persisting for more than 100 days (9, 10).

On day 1 after BHK-VSV administration, VSV-Ag was detectable in the red pulp and in the MZ of the spleen and in the marginal sinuses of MLN of TNFR1^−/− mice and controls to a similar degree; the Ag localization correlated with the presence of resident macrophages (Fig. 1⇓, A and B). By day 4, the red pulp and the MZ were already cleared of VSV-Ag. By then, VSV-Ag was colocalized with FDCs within B cell follicles of the spleen (Fig. 1⇓D) and the MLN (not shown) in control mice. VSV-specific B cells were found in B cell foci in the red pulp and the MZ, but also within B cell follicles, where the GC formation started (not shown). In contrast, in the spleen and the MLN (not shown) of TNFR1^−/− mice, no VSV-Ag (Fig. 1⇓, C vs D, d4, and E and F, d12) and no mature FDC networks (Fig. 1⇓, G vs H, d12, and a, b vs e, f) were detectable. VSV-specific B cell foci in the red pulp and scattered VSV-specific B cells were detectable in similar amounts as in controls (not shown).

• Download figure
• Open in new tab
• Download powerpoint

FIGURE 1.

Immunohistological analysis of the VSV-specific B cell response of TNFR1^−/− and control mice. Mice were immunized with VSV-infected and UV-inactivated cell lysates i.p., and the spleen sections were stained with the indicated quality. The distribution and persistence of VSV-Ag were monitored at days 1, 4, 12, and 30 after immunization, and the VSV-specific GC reaction was visualized on consecutive sections at days 12 and 30 after immunization. VSV, VSV-Ag; FDC-M1, follicular dendritic cells (FDC-M1 Ab); FDC/CD35, follicular dendritic cells (anti-CD35 Ab, 8C12); VSV-B, VSV-specific B cells; PNA, peanut hemagglutinin binding; B220/CD45RO, B220-positive B cells; IgM/IgD, double staining for IgM-positive cells (blue) and IgD-positive cells (brown); CD4, CD4-positive T cells.

By day 12 after immunization, when the GC reaction after VSV infection is maximal, all VSV-Ag detectable in control mice was localized within the GC (Fig. 1⇑F) associated with FDCs (Fig. 1⇑H) and VSV-specific B cells (Fig. 1⇑K), thus suggesting that VSV was bound to the FDCs driving this GC reaction. In addition, some VSV-specific B cell foci in the red pulp and the MZ and some scattered VSV-specific plasma cells were detectable in control mice (Fig. 1⇑K). VSV-specific plasma cells were characterized by very strong cytoplasmatic staining with VSV, whereas VSV-specific B cells show surface staining with no significant cytoplasmatic staining (9, 10). In contrast, VSV-Ag was not detectable by immunohistochemistry in spleens and MLN of TNFR1^−/− mice (Fig. 1⇑E). This suggested that mature FDCs were needed for efficient trapping of Ag and that they were lacking in TNFR1^−/− mice also after infection with VSV, as defined by no observable cell staining with the FDC-specific Ab FDC-M1 (Fig. 1⇑, G and e). Absence of networks of mature FDCs in classical GCs in TNFR1^−/− mice upon immunization with VSV was confirmed using the 8C12 Ab (Fig. 1⇑, b vs f), which recognizes complement receptor 1 or CD35 (44).

Moreover, VSV-specific B cell foci and plasma cells were detectable to a similar degree as in control mice (Fig. 1⇑I). In addition, particular accumulations of VSV-specific B cells that were PNA positive (Fig. 1⇑, I and L) were detected very rarely (1–2 per section) within the T cell area around the central arteriole of the spleen, but not in MLN (not shown). A similar PNA-positive structure has recently been described in MLN of TNFR1^−/− mice (49). Due to their aberrant localization in T areas and lack of organized structure exhibiting a dark and a light zone, the PNA⁺ B cell clusters are clearly different from classical GCs. Moreover, because PNA is generally up-regulated on recently activated B cells and also on B cells forming AFC foci in T regions (50), these pseudo-GCs most likely reflect aggregates of VSV-specific AFCs. At day 30 after infection, few VSV-specific B cells were still scattered in the red pulp and the MZ of the spleen of TNFR1^−/− mice (Fig. 1⇑T), but they gradually disappeared at earlier time points than in controls (Fig. 1⇑U).

After infection with 2 × 10⁶ PFU live VSV IND i.v., no GC were induced in TNFR1^−/− mice at any time point. The quantity and distribution of VSV-specific B cells were comparable in TNFR1^−/− and control mice with that after i.p. immunization with UV-inactivated BHK cell lysates, including the mentioned pseudo-GCs (not shown).

As additionally shown in Fig. 1⇑, X and Y, IgD⁺ B cells accumulate within the inner marginal zone in TNFR1^−/− mice and they did not form primary or secondary B cell follicles. This has been shown previously for TNF-α-deficient mice (28).

Normal neutralizing IgM and IgG responses in TNFR1^−/− mice after infection with live VSV IND and VaccIND_G

To evaluate the consequences of the lack of FDC and the inability to form GC in TNFR1^−/− mice for TI and TD B cell responses, TNFR1^−/− and control mice were infected with 2 × 10⁶ live VSV IND or VaccIND_G i.v. (Fig. 2⇓). It has been shown that the neutralizing IgM response after infection with VSV IND is of the TI-1 type, and the one after infection with VaccIND_G of the TI-2 type (51). The neutralizing IgG response is largely TD (32, 33, 52).

• Download figure
• Open in new tab
• Download powerpoint

FIGURE 2.

VSV-neutralizing IgM and IgG responses after infection with 2 × 10⁶ PFU live VSV IND i.v. (A) or with 2 × 10⁶ PFU VaccIND_G i.v. (B). Blood was taken at the indicated time points, and the neutralizing IgM (upper panels) or IgG titers (lower panels) were determined in the sera. Titers represent log₂ dilutions of 40-fold prediluted sera. ▵, TNFR1^−/− mice; ○, C57BL/6 control mice. Each line represents one individual mouse. One of three equivalent experiments is shown.

The neutralizing IgM response was similar in TNFR1^−/− mice and in controls after infection with live VSV IND. After infection with the TI-2 Ag VaccIND_G, the neutralizing IgM response was even more pronounced in TNFR1^−/− mice compared with controls probably because vaccinia virus replicated slightly better in TNFR1^−/− mice (53). Surprisingly, also the neutralizing IgG response after immunization with both viruses was similar in TNFR1^−/− mice and controls, indicating that FDCs and GCs are not a prerequisite for the isotype switch from IgM to IgG after these viral infections.

Nonreplicating Ags without adjuvant fail to induce isotype switch in TNFR1^−/− mice

UV-inactivated VSV or rVSV-G represent VSV-Ag preparations that do not replicate and, without an adjuvant, they fail to induce a significant inflammatory reaction. Both Ags induce a strong TI-neutralizing IgM response in normal mice, reflecting direct B cell activation, whereas the neutralizing IgG response is T dependent (51). The neutralizing IgM response after immunization of TNFR1^−/− mice with these nonreplicating VSV-Ags was comparable with controls (Fig. 3⇓). In contrast, TNFR1^−/− mice were not able to switch to IgG after either immunization protocol. Even priming with VSV-G and boosting 40 days later did not lead to measurable neutralizing IgG titers, and the response after boosting showed no characteristics of a secondary response (Fig. 3⇓, B and C).

• Download figure
• Open in new tab
• Download powerpoint

FIGURE 3.

VSV-neutralizing primary IgM and IgG responses after immunization with 10⁸ PFU UV-inactivated VSV IND i.v. (A) or with 10 μg VSV-G in BSS i.v. (B) and secondary neutralizing Ab responses after priming and boosting at day 40 with 10 μg VSV-G in BSS i.v. (C). Blood was taken at the indicated time points, and the neutralizing IgM (upper panels) or IgG titers (lower panels) were determined in the sera. IgM titers were absent at the time point of boosting. Titers represent log₂ dilutions of 40-fold prediluted sera. ▵, TNFR1^−/− mice; ○, C57BL/6 mice; □, control naive C57BL/6 mice receiving 10 μg VSV-G in BSS i.v. Each line represents one individual mouse. One of two equivalent experiments is shown.

If TNFR1^−/− mice were immunized s.c. with 10 μg VSV-G emulsified in IFA, leading to a slow Ag release and a modest inflammation, the neutralizing IgM response was again comparable with controls, but the switch to IgG occurred only in about 50% of the TNFR1^−/− mice. In addition, the titers were lower than in controls (Fig. 4⇓A). If VSV-G, emulsified in CFA to promote slow Ag release and considerable inflammation, was used for immunization, all TNFR1^−/− mice produced neutralizing IgM and IgG titers comparable with controls (Fig. 4⇓B).

• Download figure
• Open in new tab
• Download powerpoint

FIGURE 4.

VSV-neutralizing primary IgM and IgG responses after immunization with 10 μg VSV-G emulsified in IFA (A) or CFA s.c. (B) at the base of the tail. Mice were immunized at day 0 and blood was taken at the indicated time points, and the neutralizing IgM (upper panels) or IgG titers (lower panels) were determined in the sera. Titers represent log₂ dilutions of 40-fold prediluted sera. ▵, TNFR1^−/− mice; ○, C57BL/6 mice. Each line represents one individual mouse. One of three equivalent experiments is shown.

Kinetics of the decline of neutralizing serum IgG, of adoptively transferable B cell memory, and of AFCs in the spleen and the BM in TNFR1^−/− mice after infection with live VSV IND

The role of Ag persisting on mature FDC networks and of GCs for the maintenance of VSV-specific IgG-titers, of adoptively transferable B cell memory, and of AFCs in the spleen and the BM was evaluated by i.v. infection of TNFR1^−/− mice or control mice with 2 × 10⁶ VSV IND (Fig. 5⇓A). The neutralizing IgG titer of TNFR1^−/− mice was as high as in controls until day 30. At day 50, the IgG titer of TNFR1^−/− mice was about 5-fold reduced compared with controls. This represents a significant difference in the VSV neutralization assay. A gradual decrease in neutralizing IgG occurred in control and TNFR1^−/− mice until day 150, which was slightly more pronounced in TNFR1^−/− mice. Thereafter, a constant and high neutralizing IgG titer was maintained in controls until day 300 after immunization, whereas in TNFR1^−/− mice a further decline of circulating neutralizing IgG occurred. By day 300, the difference in neutralizing IgG between TNFR1^−/− mice and controls was about 16- to 32-fold (4–5 log₂-scale steps in Fig. 5⇓A); thus, there was a decline of about 90–97% of the neutralizing IgG titer in TNFR1^−/− mice. The same observations as for the VSV-neutralizing IgG response were made over a 300-day period for VSV-G- or VSV-N-binding IgG titers, which were determined by ELISA (data not shown).

• Download figure
• Open in new tab
• Download powerpoint

FIGURE 5.

A, VSV-neutralizing memory IgG response after infection with 2 × 10⁶ PFU live VSV IND i.v. Blood was taken at the indicated time points, and the neutralizing IgG titers were determined in the sera. Titers represent log₂ dilutions of 40-fold prediluted sera. ▵, TNFR1^−/− mice; ○, C57BL/6 control mice. Each line represents one individual mouse. One of two equivalent experiments is shown. B, Detection of adoptively transferable B cell memory in the spleen (upper panel) and of AFCs in the spleen and the BM (lower panel) at different time points after infection with 2 × 10⁶ PFU live VSV IND i.v. For detection of transferable B cell memory, 10⁷ spleen cells of VSV-infected donor mice were adoptively transferred at the indicated time points after infection into irradiated (4.5 Gy) C57BL/6 recipient mice. The recipients were challenged with 2 × 10⁶ PFU live VSV IND i.v., and the neutralizing IgG response was monitored. Each line represents the mean ± SD of at least six recipients per experimental group (two to three recipient mice/donor mouse). Donor mice: ▵, VSV-primed TNFR1^−/− mice; ○, VSV-primed C57BL/6 mice; □, naive C57BL/6 mice; ▪, no cells transferred. VSV-specific AFCs were determined in the spleen (open symbols) and the BM (filled symbols) of the same donor mice used for detection of transferable B cell memory at the indicated time points after VSV infection. Each point represents one individual mouse. Horizontal bars indicate the mean of three mice. The horizontal line indicates the detection limit of the assay. ▵ and ▴, TNFR1^−/− mice; ○ and •, C57BL/6 mice. DL, detection limit. One of two equivalent experiments is shown.

A possible explanation for the relatively long-lived IgG titers in TNFR1^−/− mice could be that VSV persists as infectious virus for prolonged time periods. To exclude this possibility, TNFR1^−/− mice and control mice were infected with VSV. One or twenty days later, brain, spinal cord, spleen, liver, and kidney were removed. The organs were homogenized, and organ homogenates were inoculated i.p. into VSV-susceptible IFN-αβR^−/− mice. It has been shown that infection with as few as 50 PFU of live VSV is lethal in IFN-αβR^−/− mice (54). Using this sensitive assay to assess viral persistence, it was possible to show that infectious VSV could be recovered from organ homogenates 1 day after VSV infection, but not 20 days after VSV infection of TNFR1^−/− and control mice (Table I⇓). Because organ homogenates from two mice were pooled for infection of one recipient animal, the detection limit of this assay was at about 25 infectious virus particles per organ.

In parallel with the decline of circulating VSV-neutralizing IgG titer, the numbers of VSV-specific AFCs in the spleen and especially in the BM declined faster in TNFR1^−/− mice than in controls (Fig. 5⇑B). Because the BM has been shown to be the major source of circulating IgG late after immunization (9, 55, 56, 57, 58), the more prominent reduction in the number of AFCs in the BM is probably responsible for the decline of circulating VSV-neutralizing IgG titers in TNFR1^−/− mice. On day 6 (Fig. 5⇑B) and day 8 (not shown), most of the AFCs were present in the spleen and only few in the BM in both TNFR1^−/− and control mice. By day 35, AFCs in the BM, but not in the spleen, were about 5-fold reduced in TNFR1^−/− mice compared with controls (28 ± 20/10⁶ BM cells vs 130 ± 53/10⁶ BM cells). Whether this reflects less efficient generation of AFCs in the spleen or LNs of TNFR1^−/− mice or reduced homing capacity of AFCs to the BM is not known. Whereas AFCs in the BM of control mice remained at this level until day 300, a further 2–3-fold decline occurred in TNFR1^−/− mice. By day 300, there was a 16-fold difference of AFCs in the BM (8 ± 5/10⁶ in TNFR1^−/− vs 133 ± 71/10⁶ BM cells in control mice) and a 3-fold difference in the spleen (12 ± 13/10⁶ vs 38 ± 18/10⁶ spleen cells) between TNFR1^−/− and control mice (Fig. 5⇑B).

In addition, the maintenance of adoptively transferable B cell memory was monitored in these mice after infection with 2 × 10⁶ PFU live VSV IND using a previously described adoptive transfer system (Fig. 5⇑B) (9). If memory B cells were present in the adoptively transferred spleen cells, a neutralizing IgG response after challenge infection with VSV IND was found to arise early in the recipients. This strong early IgG response by the transferred B cell memory was dependent on Ag challenge because adoptive transfer of B cell memory without subsequent VSV challenge did not induce a VSV-specific IgG response (not shown). The magnitude of the early memory VSV IND-specific IgG response correlated with the number of adoptively transferred memory B cells; i.e., the less memory B cells transferred, the lower the magnitude of the early memory IgG titer (Fig. 6⇓).

• Download figure
• Open in new tab
• Download powerpoint

FIGURE 6.

Correlation between the adoptive memory B cell response and the number of transferred memory B cells. Graded numbers of spleen cells originating from a VSV memory mouse (day 150 after VSV infection) were adoptively transferred into irradiated (4.5 Gy) C57BL/6 recipient mice. The recipients were challenged with 2 × 10⁶ PFU live VSV IND i.v., and the neutralizing IgG response was monitored at day 4 after challenge infection. Each bar represents the mean ± SD of at least four recipients per experimental group.

Because these adoptive transfer experiments were performed in H-2 class II-compatible, backcrossed, but not truly syngeneic recipients, we had to exclude that unexpected allogeneic effects would influence the outcome of the experiments (59, 60). First, transfer of partially allogeneic VSV-primed spleen cells without challenge infection of the recipient did not result in a measurable neutralizing IgG response. Second, transfer of naive syngeneic (C57BL/6) or partially allogeneic ((C57BL/6 × SV129)F₁) spleen cells and subsequent VSV challenge of the recipients revealed a similar neutralizing IgG response 8–12 days after challenge. Third, after adoptive transfer of primed syngeneic or primed partially allogeneic spleen cells from both strains of control mice, there was no measurable difference in the neuralizing IgG response of the recipients. This control was performed at all time points after priming (not shown). Thus, the minor undefined histocompatibility differences are unlikely to influence the outcome of the experiment.

In all adoptive transfer experiments, 2 × 10⁷ spleen cells from C57BL/6 mice that had been infected with VSV NJ 6 days previously were cotransferred with the spleen cells containing VSV-IND-specific B cell memory. This cotransfer was performed to assure nonlimiting T help for the transferred VSV IND-specific memory B cells. It has clearly been shown previously that cross-reactivity between the two VSV serotypes IND and NJ exist on the helper cell epitope level, but absolutely no cross-reactivity could be observed between these two serotypes at the level of the neutralizing B cell response (9, 45, 61). This has been confirmed for TNFR1^−/− mice (not shown).

As shown in Fig. 5⇑B, adoptively transferable B cell memory was present in both donor mouse strains at day 6 after priming. At day 35, there was no significant difference in the magnitude of transferable B cell memory between TNFR1^−/− mice and controls. Only by day 100 after infection, the controls exhibited more pronounced recirculating B cell memory in their spleens as compared with TNFR1^−/− mice, reflected by a stronger IgG response of the recipients after challenge. This difference did not significantly change until day 300. This indicated that the induction and the maintenance of transferable B cell memory in TNFR1^−/− mice were largely independent of Ag persisting on FDCs and of the GC reaction. The substantial maintenance of transferable B cell memory in TNFR1^−/− mice over more than 300 days agrees with previous reports that have shown that the transferable memory B cell pool was long-lived in mice in the absence of Ag (3, 10).

Loss of circulating VSV-specific IgG, of adoptively transferable B cell memory, and of AFC in the BM of TNFR1^−/− mice after s.c. immunization with rVSV-G in CFA

To evaluate whether these different parameters of B cell memory could also be observed in TNFR1^−/− mice after immunization with a protein Ag, mice were immunized s.c. with 10 μg VSV-G in CFA (Fig. 7⇓). CFA was used as adjuvant because TNFR1^−/− mice failed to switch to IgG similar to controls, except after immunization with VSV-G in CFA (Fig. 4⇑B). As shown in Fig. 7⇓A, the neutralizing IgG response reached similar titers in TNFR1^−/− mice and controls at day 12, and only slight differences were established until day 30. However, two of three TNFR1^−/− mice lost their IgG titers by day 70, and the other mouse showed a gradual and almost complete decline until day 200. In contrast, the IgG titers of control mice remained at a constant level from day 30 until day 200. Adoptively transferable B cell memory in the spleen was below detection level in TNFR1^−/− mice 200 days after immunization, whereas in controls it was still detectable at significant but low levels (Fig. 7⇓B). AFCs in the BM were below detection level, whereas some AFCs could still be detected in the spleen of TNFR1^−/− mice 200 days after immunization, but values from individual mice varied markedly compared with control mice (Fig. 7⇓C).

• Download figure
• Open in new tab
• Download powerpoint

FIGURE 7.

VSV-neutralizing IgG response (A), adoptively transferable VSV-specific B cell memory in the spleen (B), and AFCs in the spleen and the BM (C) after immunization with 10 μg VSV-G in CFA s.c. into the base of the tail. Mice were immunized at day 0 and blood was taken at the indicated time points, and the neutralizing IgG titers were determined in the sera (A). Titers represent log₂ dilutions of 40-fold prediluted sera. ▵, TNFR1^−/− mice; ○, C57BL/6 mice. Each line represents one individual mouse. For detection of transferable B cell memory (B), 10⁷ spleen cells of VSV-G-immunized donor mice were adoptively transferred at day 220 after immunization into irradiated (4.5 Gy) C57BL/6 recipient mice. The recipients were challenged 1 day later with 2 × 10⁶ PFU live VSV IND i.v., and the neutralizing IgG response was monitored. Each line represents the mean ± SD of at least six recipients per experimental group (two to three recipient mice/donor mouse). Donor cell origin: ▵, TNFR1^−/− mice; ○, C57BL/6 mice; □, naive C57BL/6 mice; ▪, no cells transferred. C, VSV-specific AFCs were determined ex vivo in the spleen (open symbols), and the BM (filled symbols) of the same donor mice used detection of transferable B cell memory at day 220 after VSV-G immunization. Each point represents one individual mouse. Horizontal bars indicate the mean of three mice. The horizontal line indicates the detection limit of the assay. ▵ and ▴, TNFR1^−/− mice; ○ and •, C57BL/6 mice. DL, detection limit. One of two equivalent experiments is shown.

Generation of high avidity neutralizing IgG in the spleen of TNFR1^−/− mice

To test whether the quality of the neutralizing Ab response against VSV was different in TNFR1^−/− mice and controls, B cell hybridomas were generated at two time points after infection with 2 × 10⁶ PFU VSV IND (day 12 and day 19). The mice received a booster injection of 2 × 10⁶ PFU VSV IND 3 days before the fusion. Previous studies had shown that these immunization protocols lead to the generation of high avidity neutralizing IgG in normal mice with a high neutralizing activity (36, 62). After VSV infection, the neutralizing activity of VSV-specific IgG mAbs can be used as an indicator for somatic mutation, because for some V_H families the in vitro neutralizing activity of germline Abs may be 30–100-fold lower than those of somatically mutated Abs (62). The increase in avidity for VSV binding between germline IgGs (that exhibit average avidities of 10⁻⁸ to 10⁻⁹ M⁻¹) and somatically mutated IgGs was only about 2–5-fold (62). Therefore, the increase in avidity is probably not a good indicator for the maturation of the B cell response after VSV infection. From two independent fusions of spleen cells from TNFR1^−/− mice and controls, we isolated 14 VSV-neutralizing Ab-producing clones, 7 of each mouse strain (Table II⇓). Two isolated clones produced low avidity IgM Abs. All of the remaining 6 clones from the controls produced IgG of high avidity. Assessment of the neutralizing activity of equivalent concentrations of these monoclonal IgGs showed the following results: IgGs from 2 clones (11F7 and 23D7) from the control mice exhibited intermediate neutralizing activities, whereas IgGs from the 4 other clones showed high neutralizing activities. Interestingly, the IgG Abs from the clones derived from TNFR1^−/− mice exhibited only low to intermediate, but no high neutralizing activities, suggesting that the maturation of the VSV-specific IgG response was less efficient in TNFR1^−/− mice than in controls. It has to be noted that the low to intermediate neutralizing activities of TNFR1^−/−-derived clones were not outside the range of neutralizing activities observed in clones derived from C57BL/6 mice. However, this discrepancy of the neutralizing activity of monoclonal IgG in vitro was not detectable in the polyclonal VSV-neutralizing IgG response after VSV infection in vivo (Fig. 2⇑). Although we performed sequence analysis of the V_H regions of some of these mAbs, we were not able to identify point mutations that would clearly indicate affinity maturation in TNFR1^−/− mice.